REG - Arecor Therapeutics - Director/PDMR Dealing

Arecor TherapeuticsAnnouncement

21/05/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250521:nRSU4864Ja&default-theme=true

RNS Number : 4864J  Arecor Therapeutics PLC  21 May 2025

Arecor Therapeutics plc

 

("Arecor", the "Company" or the "Group")

 

Director/PDMR Dealing

 

Cambridge, UK, 21 May 2025. Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical company advancing today's therapies to enable healthier
lives, announces that Andrew Richards (Chair), Sarah Howell (Chief Executive
Officer) and Jan Jezek (Chief Scientific Officer) have all purchased ordinary
shares of £0.01 each in the capital of the Company ("Ordinary Shares").
Details are included in the table below.

 

 Name             Number of Ordinary Shares purchased  Price (£)   Total beneficial interest (Ordinary Shares)  Total beneficial interest (%)
 Andrew Richards  31,750                               0.4697      318,361                                      0.84%
 Sarah Howell     21,077                               0.4697      905,481                                      2.40%
 Jan Jezek        10,000                               0.4700      417,808                                      1.11%

 

 

-ENDS-

 

For more information, please contact:

 

 Arecor Therapeutics plc                                 www.arecor.com
 Dr Sarah Howell, Chief Executive Officer                Tel: +44 (0) 1223 426060

                                                         Email: info@arecor.com (mailto:info@arecor.com)
 David Ellam, Chief Financial Officer                    Tel: +44 (0) 1223 426060

                                                         Email: info@arecor.com (mailto:info@arecor.com)

 Singer Capital Markets Advisory LLP (NOMAD and Broker)
 Phil Davies, Sam Butcher                                Tel: +44 (0) 20 7496 3000

 ICR Healthcare
 Chris Gardner, David Daley, Lindsey Neville             Tel: +44 (0) 20 3709 5700

                                                         Email: arecor@icrhealthcare.com (mailto:arecor@icrhealthcare.com)

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary technology platform, Arestat™, we are developing an internal
portfolio of proprietary products in diabetes and other indications, as well
as working with leading pharmaceutical and biotechnology companies to deliver
therapeutic products. The Arestat™ platform is supported by an extensive
patent portfolio.  For further details please see our website, www.arecor.com
(http://www.arecor.com)

 

 

 

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING

MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

   1    Details of the person discharging managerial responsibilities/person closely
        associated
 a)     Name                                                         Andrew Richards
 2      Reason for the notification
 a)     Position/status                                              Chair
 b)     Initial notification/Amendment                               Initial notification
 3      Details of the issuer, emission allowance market participant, auction
        platform, auctioneer or auction monitor
 a)     Name                                                         Arecor Therapeutics plc
 b)     LEI                                                          98450093D1213A8DDD58
 4      Details of the transaction(s): section to be repeated for (i) each type of
        instrument; (ii) each type of transaction; (iii) each date; and (iv) each
        place where transactions have been conducted
 a)     Description of the financial instrument, type of instrument  Ordinary Shares
 b)     Identification Code                                          GB00BMWLM973
 c)     Nature of the transaction                                    Purchase of Ordinary Shares
 d)     Price(s) and volume(s)                                        £0.4697 and 31,750 Ordinary Shares
 e)     Aggregated information                                       N/A

        - Aggregated volume

        - Aggregated price
 f)     Date of the transaction                                      19 May 2025
 g)     Place of the transaction                                     London Stock Exchange, AIM

 

   1    Details of the person discharging managerial responsibilities/person closely
        associated
 a)     Name                                                         Sarah Howell
 2      Reason for the notification
 a)     Position/status                                              Chief Executive Officer
 b)     Initial notification/Amendment                               Initial notification
 3      Details of the issuer, emission allowance market participant, auction
        platform, auctioneer or auction monitor
 a)     Name                                                         Arecor Therapeutics plc
 b)     LEI                                                          98450093D1213A8DDD58
 4      Details of the transaction(s): section to be repeated for (i) each type of
        instrument; (ii) each type of transaction; (iii) each date; and (iv) each
        place where transactions have been conducted
 a)     Description of the financial instrument, type of instrument  Ordinary Shares
 b)     Identification Code                                          GB00BMWLM973
 c)     Nature of the transaction                                    Purchase of Ordinary Shares
 d)     Price(s) and volume(s)                                        £0.4697 and 21,077 Ordinary Shares
 e)     Aggregated information                                       N/A

        - Aggregated volume

        - Aggregated price
 f)     Date of the transaction                                      19 May 2025
 g)     Place of the transaction                                     London Stock Exchange, AIM

 

   1    Details of the person discharging managerial responsibilities/person closely
        associated
 a)     Name                                                         Jan Jezek
 2      Reason for the notification
 a)     Position/status                                              Chief Scientific Officer
 b)     Initial notification/Amendment                               Initial notification
 3      Details of the issuer, emission allowance market participant, auction
        platform, auctioneer or auction monitor
 a)     Name                                                         Arecor Therapeutics plc
 b)     LEI                                                          98450093D1213A8DDD58
 4      Details of the transaction(s): section to be repeated for (i) each type of
        instrument; (ii) each type of transaction; (iii) each date; and (iv) each
        place where transactions have been conducted
 a)     Description of the financial instrument, type of instrument  Ordinary Shares
 b)     Identification Code                                          GB00BMWLM973
 c)     Nature of the transaction                                    Purchase of Ordinary Shares
 d)     Price(s) and volume(s)                                        £0.4700 and 10,000 Ordinary Shares
 e)     Aggregated information                                       N/A

        - Aggregated volume

        - Aggregated price
 f)     Date of the transaction                                      20 May 2025
 g)     Place of the transaction                                     London Stock Exchange, AIM

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHAMMRTMTBTBJA